Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Oral Investigations
Published in: Clinical Oral Investigations 5/2019

01-05-2019 | Original Article

Bone repair in craniofacial defects treated with different doses of alendronate: a histological, histomorphometric, and immunohistochemical study

Authors: Naylin de Oliveira, Jefferson Oliveira, Letícia de Souza Moraes, Suyany Gabriely Weiss, Luís Henrique Chaves, Thais Costa Casagrande, Tatiana Miranda Deliberador, Allan Fernando Giovanini, João César Zielak, Rafaela Scariot

Published in: Clinical Oral Investigations | Issue 5/2019

Login to get access

Abstract

Objective

The objective of the study is to evaluate bone repair in rats treated with different alendronate doses.

Matherials and methods

Sixty female rats ovariectomized were randomly divided in three groups: group C (control group), group A1 (ALN/1 mg/kg), and A2 (ALN/ 3 mg/kg). Each animal received subcutaneous applications of sodium alendronate at a dose correspondent to group A1 or A2 three times a week, while the control group received 0.9% saline solution. After 4 weeks of application, a critical defect was created in the calvaria of animals of all groups. The defect was filled by particulate autogenous bone. The applications were maintained until euthanasia, which occurred 15 and 60 days after the surgical procedure. The pieces were sent for histological, histomorphometric and immunohistochemical analysis. The data were submitted to statistical analysis with significance level of 0.05.

Results

The descriptive histological analysis demonstrated an increase in bone neoformation in both groups treated with alendronate when compared to the control group. The histomorphometric analysis showed an increase in the amount of neoformed bone in A1 and A2 groups when compared to group C, both at 15 days (p = 0.0002) and at 60 days (p = 0.001). In the immunohistochemical analysis, it was possible to observe a difference in immunolabeling just for Mmp2 at the time of 60 days in A1 (p = 0.001) and A2 (p = 0.023) when compared to the control group.

Conclusion

Systemic delivery of alendronate, regardless of the dose, increased the amount of bone neoformation.

Clinical relevance

Prescription of sodium alendronate at 1 mg/kg for improvement of bone neoformation in bone graft procedures.
Literature
1.
Chaudhry AN, Ruggiero SL (2007) Osteonecrosis and bisphosphonates in oral and maxillofacial surgery. Oral Maxillofac Surg Clin N Am 19:199–206CrossRef
2.
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Richard P et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRefPubMed
3.
Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005 Dec;136(12):1658–68. Review. Erratum in: J Am Dent Assoc. 2006 Jan;137(1):26
4.
Kim JH, Park YB, Li Z, Shim JS, Moon HS, Jung HS, Chung MK (2011) Effect of alendronate on healing of extraction sockets and healing around implants. Oral Dis 17:705–711CrossRefPubMed
5.
Toker H, Ozdemir H, Ozer H, Eren K (2012) A comparative evaluation of the systemic and local alendronate treatment in synthetic bone graft: a histologic and histomorphometric study in a rat calvarial defect model. Oral Surg Oral Med Oral Pathol Oral Radiol 114(5 Suppl):S146–S152CrossRefPubMed
6.
Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237–2246CrossRefPubMed
7.
Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technology Assessment 2014; 18 (11)
8.
Scully C, Madrid C, Bagan J (2006) Dental endosseous implants in patients on bisphosphonate therapy. Implant Dent 15:212–215CrossRefPubMed
9.
Migliorati CA, Siegel MA, Elting LS (2006) Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7(6):508–514CrossRefPubMed
10.
11.
De Boer J, Wang HJ, Van Blitterswijk C. Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng 2004; 10(3–4):393–401
12.
13.
Jabłońska-Trypuć A, Matejczyk M, Rosochacki S (2016) Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem 31(1):177–183CrossRef
14.
Nagase H, Woessner JF (1999) Matrix metalloproteinases. J Oral Chem 274:21491–21494
15.
16.
Zhao H, Bernardo MM, Osenkowski P, Sohail A, Pei D, Nagase H, Kashiwagi M, Soloway PD, DeClerck YA, Fridman R (2004) Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem 279(10):8592–8601 Epub 2003 Dec 16CrossRefPubMed
17.
John M, Jaworski C, Chen Z, Subramanian S, Ma W, Sun F, Li D, Spector A, Carper D (2004) Matrix metalloproteinases are down-regulated in rat lenses exposed to oxidative stress. Exp Eye Res 79(6):839–846CrossRefPubMed
18.
Fernandes C, Leite RS, Lanças FM (2005) Bisfosfonatos: síntese, análises químicas e aplicações farmacológicas. Quím Nova 28(2):274–280CrossRef
19.
Buzza JA III, Einhorn T (2016) Bone healing in 2016. Clin Cases Miner Bone Metab 13(2):101–105
20.
Riggs BL, Melton LJ III (1992) The prevention and treatment of osteoporosis. N EngI J Med 327:620–627CrossRef
21.
Sun JS, Huang YC, Tsuang YH, Chen LT, Lin FH (2001) Sintered dicalcium pyrophosphate increases bone mass in ovariectomized rats. J Biomed Mater Res 59(2):246–253CrossRef
22.
WHO technical report series, No. 843: (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. Geneva: World Health Organization
23.
Toker H, Ozdemir H, Ozer H, Eren K (2012) Alendronate enhances osseous healing in a rat calvarial defect model. Elsevier 57:1545–1550
24.
25.
Boland GM, Perkins G, Hall DJ, Tuan RS (2004) Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93(6):1210–1230CrossRefPubMed
26.
Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102:3324–3329CrossRefPubMedPubMedCentral
27.
Luo Q, Kang Q, Si W, Jiang W, Park JK, Peng Y et al (2004) Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279:55958–55968CrossRefPubMed
28.
Nyman JS, Lynch CC, Perrien DS, Thiolloy S, O’Quinn EC, Patil CA, Bi X, Pharr GM, Mahadevan-Jansen A, Mundy GR (2011) Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res 26(6):1252–1260CrossRefPubMed
29.
De Simone E, Caggiano N, Polli M, Rolando J, Lastra Y, Gullace F et al (2013) Efecto del alendronato sobre el perfil de citoquinas y metaloproteinasas 2 y 9 en un modelo múrido de artritis experimental. Rev Colomb Reumatol 20(4):202–210
30.
Hashimoto K, Morishige K, Sawada K, Tahara M, Shimizu S, Ogata S, Sakata M, Tasaka K, Kimura T (2007) Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 354(2):478–484CrossRefPubMed
31.
Hashimoto K, Morishige K, Sawada K, Tahara M, Kawagishi R, Ikebuchi Y et al (2005 Jan 15) Alendronate inhibits intraperitoneal dissemination in vivo ovarian cancer model. Cancer Res 65(2):540–545PubMed
Metadata
Title
Bone repair in craniofacial defects treated with different doses of alendronate: a histological, histomorphometric, and immunohistochemical study
Authors
Naylin de Oliveira
Jefferson Oliveira
Letícia de Souza Moraes
Suyany Gabriely Weiss
Luís Henrique Chaves
Thais Costa Casagrande
Tatiana Miranda Deliberador
Allan Fernando Giovanini
João César Zielak
Rafaela Scariot
Publication date
01-05-2019
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 5/2019
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-018-2670-0

Other articles of this Issue 5/2019

Clinical Oral Investigations 5/2019 Go to the issue

Abstracts

ConsEuro Conference 2019, Berlin, June 14-15

Original Article

Prevention of oral carcinogenesis in rats by Dracaena cinnabari resin extracts

Original Article

Effect of different sizes of bioactive glass-coated mesoporous silica nanoparticles on dentinal tubule occlusion and mineralization

Original Article

The effect of age, gender, and time between blood draw and start of centrifugation on the size outcomes of platelet-rich fibrin (PRF) membranes

Original Article

Comparative evaluation of autofluorescence imaging and histopathological investigation for oral potentially malignant disorders in Taiwan

Original Article

Cyclic fatigue of Reciproc Blue and Reciproc instruments exposed to intracanal temperature in simulated severe apical curvature